Opiant Pharmaceuticals, Inc. (Opiant), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced that the last patient has been enrolled in the phase 2 clinical trial of OPNT002, nasal naltrexone, for patients with alcohol use disorder (AUD). The total trial duration per patient is 20 weeks, with the last patient enrolled expected to complete the study in early 2023 and with top line data anticipated to follow mid-year.
"We are pleased to have completed patient enrollment ahead of schedule and are looking forward to concluding the treatment phase of this study and releasing top-line data next year,
